α-氨基羥甲基 唑丙酸（AMPA）受體廣泛分布于具有興奮性的神經(jīng)突觸中，在中樞神經(jīng)系統(tǒng)中起著重要作用，神經(jīng)退行性障礙、行動(dòng)障礙、精神疾病、疼痛等許多疾病都涉及到AMPA受體。日本Eisai公司的在研新藥Perampanel（E2007）作為首個(gè)具有高度選擇性和非競(jìng)爭(zhēng)性的AMPA型谷氨酸鹽受體拮抗劑，用于治療難治性癲癇的部分發(fā)作。基于3個(gè)Ⅲ期臨床試驗(yàn)具有良好結(jié)果，2011年該公司已向美國(guó)和歐洲提交了該藥物的營(yíng)銷許可申請(qǐng)。

The AMPA receptor is widely present in almost all excitatory neuronal synapses. It is believed to play a role in a large number of central nervous system diseases with different underlying pathophysiology, including neurodegenerative disorders, movement disorders, pain and psychiatric disorders. Eisai that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound Perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of refractory partial seizures in patients with epilepsy.